Nicotinamide Riboside
Also known as: NR, Nicotinamide riboside chloride
Randomized human trials and systematic reviews show that oral NR reliably increases blood NAD+ and, in some trials, brain NAD levels. Trials to date report good tolerability and biochemical target engagement, but evidence for consistent clinical benefits on cognition, vascular function or other ageing-related outcomes is heterogeneous and frequently null.
Last reviewed: 2026-10-14 · 5 indexed studies
Set your location for accurate regulatory status
Saved on this device — no sign-in needed.
Overview
Nicotinamide riboside (NR) is an orally available NAD+ precursor used to raise cellular and circulating NAD+ levels. Human trials report biochemical target engagement and generally good tolerability, while effects on functional or clinical endpoints are variable and often inconclusive.
Mechanism & Function
Mechanism of Action
NR is metabolised to NAD+, a central cofactor for redox reactions and NAD+-dependent enzymes (e.g. sirtuins). Increased NAD+ can modulate mitochondrial function, cellular metabolism, inflammatory signalling and transcriptional programmes related to proteostasis, as suggested by changes in metabolites and gene expression in blood and muscle in human studies.
Physiological Role
Supports cellular NAD+ pools necessary for energy metabolism, mitochondrial function, and NAD+-dependent signalling pathways.
Primary Pathways
Performance / Health Relevance
By raising NAD+ and altering mitochondrial and inflammatory pathways, NR has plausible relevance for metabolic health, cellular resilience and neuroprotection, but clinical performance effects have not been consistently demonstrated in trials provided here.
Evidence Review
Compare Vitamin B3 (Niacin) Forms
Full comparison5 vitamin b3 (niacin) forms are indexed. Bioavailability, clinical evidence, and best-use cases differ meaningfully between them.
| Form | Evidence |
|---|---|
Nicotinamide RibosideThis page Oral NR increases circulating NAD+ and, in at least one trial, brain NAD+; magnitude of change is variable between individuals. | 61/100 |
| Vitamin B3 (Niacin) Both nicotinic acid and nicotinamide are well absorbed orally. Nicotinic acid has varying pharmacokinetic profiles depending on the formulation (immediate-release vs. sustained-release). | 80/100 |
| Vitamin B3 (Niacinamide) Highly bioavailable orally, with absorption rates typically exceeding 90%. | 65/100 |
| NMN Oral NMN raises plasma NAD+; sublingual delivery may improve bypass of gut conversion. | 54/100 |
| Nicotinamide Mononucleotide Rapidly absorbed and converted to NAD+ within 30 minutes. Some degradation by CD73 ectoenzyme in the GI tract — sublingual delivery may improve yield. | 50/100 |
Practical Use & Dosage
- Minimum Effective Dose
- 1 g/day (observed to increase blood and, in one trial, brain NAD+)
- Optimal Range
- 1 g/day (doses in the provided trials)
- Upper / Caution Level
- Not established
- Timing
- Oral, daily
- Best Format
- Oral capsule/tablet
- Bioavailability
- Oral NR increases circulating NAD+ and, in at least one trial, brain NAD+; magnitude of change is variable between individuals.
- Absorption Considerations
- NR is orally bioavailable and elevates blood NAD+ within weeks; individual response may vary.
Safety & Interactions
Side Effects
- •Generally well tolerated in trials; no consistent increase in adverse events reported
Contraindications
- Not established in provided abstracts
Drug Interactions
- •Not established in provided abstracts
Who Should Avoid
- •Not established in provided abstracts; pregnant or breastfeeding individuals not evaluated in the provided trials
Monitoring
Clinical monitoring should follow standard medical guidance; trials measured NAD+ and some inflammatory markers but routine clinical monitoring recommendations are not established here.
Frequently Asked Questions
Auto-generated from indexed evidence — dosage, safety, interactions, and more.
When is Nicotinamide Riboside typically used or indicated?
Nicotinamide Riboside is most commonly used for: NAD+ boosting, Age-related metabolic support, Cognitive health research. Supports cellular NAD+ pools necessary for energy metabolism, mitochondrial function, and NAD+-dependent signalling pathways.
How does Nicotinamide Riboside work?
NR is metabolised to NAD+, a central cofactor for redox reactions and NAD+-dependent enzymes (e.g. sirtuins). Increased NAD+ can modulate mitochondrial function, cellular metabolism, inflammatory signalling and transcriptional programmes related to proteostasis, as suggested by changes in metabolites and gene expression in blood and muscle in human studies.
What is the recommended dose of Nicotinamide Riboside?
The optimal range is 1 g/day (doses in the provided trials). with a minimum effective dose of 1 g/day (observed to increase blood and, in one trial, brain NAD+). Best taken: Oral, daily. Upper / caution level: Not established.
What are the side effects of Nicotinamide Riboside?
Reported side effects include: Generally well tolerated in trials; no consistent increase in adverse events reported. Monitoring: Clinical monitoring should follow standard medical guidance; trials measured NAD+ and some inflammatory markers but routine clinical monitoring recommendations are not established here.
Does Nicotinamide Riboside interact with medications?
Known or theoretical interactions: Not established in provided abstracts. Always check with a clinician before combining with prescription medication.
Who should avoid Nicotinamide Riboside?
Nicotinamide Riboside is generally not recommended for: Not established in provided abstracts; pregnant or breastfeeding individuals not evaluated in the provided trials; and Not established in provided abstracts.
How strong is the evidence for Nicotinamide Riboside?
Evidence level: Moderate (overall score 61/100), based on 5 indexed studies on SuppIndex.
Research & References (5)
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Double-blind randomized phase I trial in newly diagnosed, treatment-naive Parkinson's disease patients receiving 1,000 mg NR or placebo for 30 days; assessed cerebral NAD by 31P-MRS, CSF metabolites, PET metabolism, blood/muscle transcriptional changes and inflammatory cytokines.
A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment.
Placebo-controlled randomized pilot study in older adults with mild cognitive impairment using dose escalation to 1 g/day over 10 weeks; primary outcome was change in MoCA; secondary outcomes included cerebral blood flow, blood NAD+, cognitive and physical measures, and DNA methylation in PBMCs.
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.
Randomized, double-blind, placebo-controlled crossover trial in healthy middle-aged and older adults (two 6-week periods) assessing tolerance and stimulation of NAD+ metabolism with chronic NR supplementation.
NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.
PRISMA-guided systematic review (2010–Oct 2025) of preclinical and clinical NAD+-related compound interventions, identifying 33 human intervention studies and 80 rodent studies.
Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach.
Systematic review focused on NAD+ precursors for Alzheimer's disease, surveying recent preclinical and clinical studies of NMN and NR.
Related Ingredients
Other top-rated ingredients in General Health Ingredients.
Piperine
82/100A piperidine alkaloid (C₁₇H₁₉NO₃) that inhibits cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2E1), P-glycoprotein efflux transporters, and UDP-glucuronosyltransferases while enhancing intestinal permeability, digestive enzyme secretion, and splanchnic blood flow — collectively producing dramatic improvements in nutrient bioavailability.
CoQ10
78/100Endogenous lipid-soluble ubiquinone/ubiquinol that shuttles electrons in the mitochondrial respiratory chain and acts as a membrane antioxidant.
Beta-Glucan (Oat)
77/100Multiple randomized trials and meta-analyses report that ≥3 g/day oat beta-glucan lowers LDL and total cholesterol modestly. Acute feeding trials pooled in meta-analysis show dose- and molecular-weight–dependent reductions in postprandial glucose and insulin responses.
Research Overview
Moderate EvidenceCite this ingredient
One-click citation export in APA, MLA, Chicago, BibTeX, or HTML. The URL below is stable and safe to link.
Stable URL
https://thesuppindex.com/ingredients/nicotinamide-riboside
SuppIndex. (2026). Nicotinamide Riboside: Evidence summary, dosage and clinical studies. Retrieved October 16, 2026, from https://thesuppindex.com/ingredients/nicotinamide-riboside
Based on 5 indexed studies · Evidence level: Moderate.
Goal Ratings
Stack Compatibility
No specific interaction data reported in the provided abstracts; NR is commonly studied alongside other metabolic or mitochondrial interventions but combination safety/effectiveness requires direct evidence.